within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M09A_OtherDrugsForDisordersOfTheMusculoSkeletalSystem.M09AX06_Eteplirsen;

model Eteplirsen
  extends Pharmacolibrary.Drugs.ATC.M.M09AX06;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>M09AX06</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Eteplirsen is an antisense oligonucleotide designed to treat Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping. It is administered intravenously and is approved for use in several countries including the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from clinical studies in pediatric male subjects with Duchenne muscular dystrophy (DMD) aged 7-13 years receiving repeated intravenous infusions.</p><h4>References</h4><ol><li><p>Mercuri, E, et al., &amp; Muntoni, F (2023). Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6-48 months with Duchenne muscular dystrophy amenable to exon 51 skipping. <i>Neuromuscular disorders : NMD</i> 33(6) 476–483. DOI:<a href=\"https://doi.org/10.1016/j.nmd.2023.03.008\">10.1016/j.nmd.2023.03.008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37207382/\">https://pubmed.ncbi.nlm.nih.gov/37207382</a></p></li><li><p>Goey, AKL, et al., &amp; East, L (2024). Characterization of Nonclinical Drug Metabolism and Pharmacokinetic Properties of Phosphorodiamidate Morpholino Oligonucleotides, a Novel Drug Class for Duchenne Muscular Dystrophy. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 52(12) 1396–1406. DOI:<a href=\"https://doi.org/10.1124/dmd.124.001819\">10.1124/dmd.124.001819</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39516029/\">https://pubmed.ncbi.nlm.nih.gov/39516029</a></p></li><li><p>Patel, Y, et al., &amp; East, L (2025). A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 14(5) 891–903. DOI:<a href=\"https://doi.org/10.1002/psp4.70001\">10.1002/psp4.70001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40009522/\">https://pubmed.ncbi.nlm.nih.gov/40009522</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Eteplirsen;
